Med-tech makers could see an earlier payoff by looking at ways to deliver drug therapy with their devices, MIT researcher Michael Cima says. Companies combining valuable devices with known drugs may be able to land a high-value exit before ever hitting the market, MIT researcher Michael Cima told a group of medical device industry leaders today.
